化学
冠状病毒
药理学
2019年冠状病毒病(COVID-19)
2019-20冠状病毒爆发
病毒学
内科学
医学
生物
爆发
传染病(医学专业)
疾病
作者
Dorothée Bardiot,David C. McGowan,Kusum Gupta,Jérôme Deval,Sandra P. Chang,Andreas Jekle,Liu C,Sarah Stevens,Vladimir Serebryany,Marcel J Tauchert,K. Maskos,Antitsa Stoycheva,Suping Ren,Ruchika Jaisinghani,Marine O. Faucher,Tse‐I Lin,Sandro Boland,Patrick Chaltin,Arnaud Marchand,Jurgen Wuyts
标识
DOI:10.1021/acs.jmedchem.5c00088
摘要
) indicated the potential for BID dosing without the need for ritonavir, the PK boosting component of Paxlovid. After preclinical safety and pharmacological studies, ALG-097558 has progressed to phase 1 clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI